Perspectives for targeted therapies in cancer of unknown primary site

Cancer Treatment Reviews

Volumn 32, Issue 8, 2006, Pages 637-644

  Pentheroudakis, George ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer; Oncogenes; Targeted therapy; Unknown primary

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CD34 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GELATINASE B; IMATINIB; LAPATINIB; LONAFARNIB; OBLIMERSEN; ONYX 015; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; TIPIFARNIB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG RESPONSE; DRUG TARGETING; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; ONCOGENES;

EID: 33750477685     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.08.004     Document Type: Review

References (48)

1. Pavlidis N., and Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 54 (2005) 243-250
2. Levi F., Te V.C., Erler G., Randimbison L., and La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer 38 (2002) 1810-1812
3. Coates M, Armstrong B. NSW Central Cancer Registry. Cancer in New South Wales. Incidence and Mortality. NSW, Cancer Council; 1995.
4. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
5. Pentheroudakis G., Briasoulis E., Karavasilis V., Fountzilas G., Xeros N., et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?. Acta Oncol 44 (2005) 155-160
6. Van de Wouw A.J., Jansen R.L.H., Speel E.J.M., and Hillen H.F.P. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 14 (2003) 191-196
7. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev 4 (2004) 361-370
8. Hortobagyi G.N. Trastuzumab in the treatment of breast cancer. N Engl J Med 353 (2005) 1734-1736
9. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., et al. Bevacizumab plus irinotecan, 5-fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
10. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res 49 (1989) 4682-4689
11. Long S.B., Hancock P.J., Kral A.M., et al. The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics. Proc Natl Acad Sci USA 98 (2001) 12948-12953
12. Pavlidis N., Briasoulis E., Bai M., Fountzilas G., and Agnanti N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 15 (1995) 2563-2567
13. Appels N., Beijnen J.H., and Schellens J. Development of farnesyl-transferase inhibitors: a review. The Oncologist 10 (2005) 565-578
14. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
15. Hainsworth J.D., Lennington W.J., and Greco F.A. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18 (2000) 632-635
16. Fizazi K., Voigt J.J., Lesimple T., Lortholary A., Bugat R., et al. Carcinoma of unknown primary (CUP): are the tyrosine kinase receptors HER-2, EGF-R, and c-Kit suitable targets for therapy?. Proc Am Soc Clin Oncol 22 (2003) 3549 [abstr.]
17. Van de Wouw A.J., Jansen R.L., Griffioen A.W., and Hillen H.F. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 24 (2004) 297-301
18. Rashid A., Hess K.R., Lenzi R., Raber M.N., Abbruzzese J.L., et al. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). Proc Am Soc Clin Oncol 24 (2005) 9683 [abstr.]
19. Baselga J., and Arteaga C.L. Critical update and emerging trends in Epidermal Growth Factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
20. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
21. Bonner J.A., Harari P.M., Giralt J., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proc Am Soc Clin Oncol 23 (2004) 5507
22. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
23. Dova L., Georgiou I., Vartholomatos G., Kolaitis N., Malamou-Mitsi V., et al. EGFR and C-KIT/CD117 gene mutational screening and oncoprotein expression in patients with cancer of unknown primary: implications for molecular pathophysiology and therapy. Eur J Cancer 3 2 (2005) 424 [abstr 1466]
24. Eberhard D.A., Johnson B.E., Amler L.C., et al. Mutations in the EGFR and in KRAS are predictive and prognostic indicators in patients with NSCLC treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
25. Engelman J., Janne P., Mermel C., Pearlberg J., Mukohara T., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. PNAS 102 (2005) 3788-3793
26. Corless C.L., Fletcher J.A., and Heinrich M.C. Biology of gastrointestinal stromal tumours. J Clin Oncol 22 (2004) 3813-3825
27. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
28. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998) 1322-1326
29. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4 (2003) 721-729
30. Briasoulis E., Tsokos M., Fountzilas G., et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Cooperative Oncology Group study. Anticancer Res 18 (1998) 1907-1914
31. Holstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
32. Cohen E.E., and Rudin C.M. ONYX-015. Onyx pharmaceuticals. Curr Opin Investig Drugs 2 (2001) 1770-1775
33. Ding K., Lu Y., Nikolovska-Coleska Z., Wang G., Qiu S., et al. Structure-based design of spiro-oxindoles as potent, specific small molecule inhibitors of the MDM2-p53 interaction. J Med Chem 49 (2006) 3432-3435
34. Bar-Eli M., Abbruzzese J.L., Lee-Jackson D., and Frost P. p53 gene mutation spectrum in human unknown primary tumours. Anticancer Res 13 (1993) 1619-1623
35. Vousden K.H., and Woude G.F. The ins and outs of p53. Nat Cell Biol 2 (2000) E178-E180
36. Naresh K.N. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? - a hypothesis. Med Hypotheses 59 (2002) 357-360
37. Sandler A., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Proc Am Soc Clin Oncol 23 (2005) 2s [Abstract LBA4]
38. Miller K.D., Wang M., Gralow J., et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Proc Am Soc Clin Oncol 23 (2005) LBA
39. Motzer R.J., Hoosen S., Bello C.L., and Christensen J.G. Sunitinib maleate for the treatment of solid tumours: a review of current clinical data. Expert Opin Invest Drugs 15 (2006) 553-561
40. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 23 (2005) 380s [Abstract LBA4510]
41. Hillen H.F., Hak L.E., Joosten-Achjanie S.R., and Arends J.W. Microvessel density in unknown primary tumours. Int J Cancer 74 (1997) 81-85
42. Karavasilis V., Malamou-Mitsi V., Briasoulis E., Tsanou E., Kitsou E., et al. Angiogenesis in cancer of unknown primary: a clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 5 (2005) 25-32
43. Karavasilis V., Malamou-Mitsi V., Briasoulis E., Tsanou E., Kitsou E., et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 104 (2005) 2282-2287
44. Hainsworth J.D., Spigel D.R., Thompson D.S., Shipley D.L., Zubkus J.D., et al. Bevacizumab plus erlotinib in patients with carcinomas of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Proc Am Soc Clin Oncol 24 (2006) 129s [Abstract 3033]
45. Frank R.C., Kaplan F., and Nair S. Response of carcinoma of unknown primary site affecting bone to thalidomide. Lancet Oncol 6 (2005) 534-535
46. Tothill R.W., Kowalczyk A., Rischin D., Bousioutas A., Haviv I., et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65 (2005) 4031-4040
47. Dennis J.L., Hvidsten T.R., Wit E.C., Komorowski J., Bell A.K., et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11 (2005) 3766-3772
48. Ramaswamy S., Ross K.N., Lander E., and Golub T.R. A molecular signature of metastasis in primary solid tumours. Nat Genet 33 (2003) 49-54